11.21.25 -- 100% Drug Tariffs Are A Dire Threat — And Patients Can't Wait

Condition-based matching is replacing the inefficient, study-by-study model with a patient-centric approach that matches individuals to all relevant trials based on their unique medical profiles.

Examine the treatment landscape for rare diseases and the rapid evolution of gene therapy across three key dimensions: editing platforms, delivery modalities, and delivery vehicles.

The patient voice is now critical in evaluating new drug treatments. Learn how health technology assessment agencies incorporate patient-reported outcomes to move beyond traditional clinical endpoints.

A $249M investment by Ypsomed will bring 62 new jobs and a cutting-edge auto-injector facility to Holly Springs, reinforcing the region’s role in biomanufacturing and drug delivery innovation.

Noncompliance with clinical trial disclosure regulations can jeopardize M&A deals. Understanding FDA and SEC requirements is critical to avoid red flags during due diligence.

Take a deeper look at AI-enabled translations and uncover how they are able to drive a remarkable 43% reduction in overall translation timelines.

Building an "analytics culture" in clinical research requires striking a balance between fast, flexible technologies and the right support for trial teams working to integrate these solutions.